SCNX on Nasdaq
Scienture Holdings, Inc.
American pharmaceutical preparations company based in Commack. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with XTL Bio, MEDICINOVA INC or Can Fite Biopharma, or pick any stock.
- TickerSCNX on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersCommack, New York1
- Incorporated inDE2
- Business address20 Austin Blvd., Commack, Ny 117252
- Filer categoryNon-accelerated filer, Smaller reporting company2
- Legal formCorporation
See how the biggest companies compare on our leaderboards
LLC became a wholly owned subsidiary of the Company. Scienture’s principal executive offices are located in Commack, New York.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
76.8%Gross margin4
-9867.9%Operating margin4
-9618.0%Net margin4
215.9%Revenue growth, 20254
-59.2%Return on equity4
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue2¢$100.1K
- Research and development48¢$2.0M
- Income tax49¢$2.0M
Out of $431.6K in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenues | $431.6K | $136.6K |
| Cost of sales | $100.1K | $130.6K |
| Gross profit | $331.5K | $6.0K |
| Wage and salary expense | $2.1M | $2.1M |
| Professional fees | $2.4M | $1.5M |
| Accounting and legal expense | $2.1M | $1.8M |
| Technology expense | $97.3K | $416.3K |
| General and administrative | $7.9M | $6.7M |
| Research and development | $2.0M | $2.2M |
| Impairment loss | $26.3M | |
| Total operating expenses | $42.9M | $14.7M |
| Operating loss | -$42.6M | -$14.7M |
| Change in fair value of warrant liability | $909.0K | -$183.0K |
| Change in fair value of derivative liability | $2.3M | $180.4K |
| Impairment of investment | -$2.5M | |
| Loss on conversion of note payable | -$53.4K | |
| Loss on disposition of subsidiaries | -$288.2K | |
| Interest income | $302.7K | $135.3K |
| Loss on disposal of asset | -$375.0K | |
| Interest expense | -$4.1M | -$1.3M |
| Total non-operating expense | -$916.3K | -$4.1M |
| Net loss from continuing operations | -$43.5M | -$18.8M |
| Benefit / (provision) for income taxes | $2.0M | $534.4K |
| Net loss from continuing operations, net of tax | -$41.5M | -$18.2M |
| Net income from discontinued operations, net of tax | $27.3M | |
| Net (loss) income | -$41.5M | $9.1M |
| Basic | -$3 | -$5 |
| Diluted | -$3 | -$5 |
| Basic | $8 | |
| Diluted | $7 | |
| Basic | -$2.70 | $2.69 |
| Diluted | -$2.70 | $2.48 |
| Basic | 15.3M shares | 3.4M shares |
| Diluted | 15.3M shares | 3.7M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $6.7M | $308.1K | |
| Accounts receivable, net | $731.3K | $11.1K | |
| Inventory | $213.4K | ||
| Prepaid expenses | $262.3K | $4.6K | |
| Other receivables | $4.1M | ||
| Deferred offering costs | $47.4K | $534.8K | |
| Current assets of discontinued operations | $8.1K | ||
| Total current assets | $7.9M | $6.3M | |
| Property, plant and equipment, net | $15.5K | $17.5K | |
| Deposits | $22.0K | ||
| Notes receivable | $5.0M | ||
| Interest receivable | $250.0K | ||
| Intangible assets, net | $71.0M | $76.4M | |
| Goodwill | $21.4M | ||
| Operating lease right-of-use assets | $23.4K | $201.4K | |
| Deferred tax asset | $534.4K | ||
| Total assets | $84.2M | $104.9M | |
| Accounts payable | $1.4M | $2.9M | |
| Accrued liabilities | $657.0K | $1.3M | |
| Other current liabilities | $5.4K | ||
| Loan payable, related party | $415.0K | ||
| Convertible note, net of debt discount - current portion | $2.3M | ||
| Operating lease liability - current | $24.1K | $63.3K | |
| Warrant liability | $10.9K | $919.9K | |
| Development agreement liability - current portion | $600.0K | ||
| Current liabilities of discontinued operations | $5.3K | ||
| Total current liabilities | $2.7M | $7.9M | |
| Convertible notes, net of debt discount | $612.3K | ||
| Derivative liability | $2.3M | ||
| Operating lease liability - net of current portion | $156.5K | ||
| Development agreement liability | $285.0K | $1.3M | |
| Deferred tax liability | $11.0M | $13.5M | |
| Total liabilities | $14.1M | $25.8M | |
| Common stock, $0.00001 par value; 100,000,000 shares authorized; 40,630,815 and 8,750,582 shares issued and outstanding as of December 31, 2025 and 2024, respectively 1,015,000 and 0 shares unvested as of December 31, 2025 and 2024, respectively | $406 | $87 | |
| Additional paid-in capital | $150.7M | $118.1M | |
| Accumulated deficit | -$80.6M | -$39.0M | |
| Total stockholders equity | $70.1M | $79.1M | $542.4K |
| Total liabilities and stockholders equity | $84.2M | $104.9M | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 100.0M shares | 100.0M shares | |
| Common stock, shares issued | 40.6M shares | 8.8M shares | |
| Common stock, shares outstanding | 40.6M shares | 8.8M shares | |
| Common stock, shares unvested | 1.0M shares | 0 shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $6.7M | $308.1K | |
| Accounts receivable, net | $731.3K | $11.1K | |
| Inventory | $213.4K | ||
| Prepaid expenses | $262.3K | $4.6K | |
| Other receivables | $4.1M | ||
| Deferred offering costs | $47.4K | $534.8K | |
| Current assets of discontinued operations | $8.1K | ||
| Total current assets | $7.9M | $6.3M | |
| Property, plant and equipment, net | $15.5K | $17.5K | |
| Deposits | $22.0K | ||
| Notes receivable | $5.0M | ||
| Interest receivable | $250.0K | ||
| Intangible assets, net | $71.0M | $76.4M | |
| Goodwill | $21.4M | ||
| Operating lease right-of-use assets | $23.4K | $201.4K | |
| Deferred tax asset | $534.4K | ||
| Total assets | $84.2M | $104.9M | |
| Accounts payable | $1.4M | $2.9M | |
| Accrued liabilities | $657.0K | $1.3M | |
| Other current liabilities | $5.4K | ||
| Loan payable, related party | $415.0K | ||
| Convertible note, net of debt discount - current portion | $2.3M | ||
| Operating lease liability - current | $24.1K | $63.3K | |
| Warrant liability | $10.9K | $919.9K | |
| Development agreement liability - current portion | $600.0K | ||
| Current liabilities of discontinued operations | $5.3K | ||
| Total current liabilities | $2.7M | $7.9M | |
| Convertible notes, net of debt discount | $612.3K | ||
| Derivative liability | $2.3M | ||
| Operating lease liability - net of current portion | $156.5K | ||
| Development agreement liability | $285.0K | $1.3M | |
| Deferred tax liability | $11.0M | $13.5M | |
| Total liabilities | $14.1M | $25.8M | |
| Common stock, $0.00001 par value; 100,000,000 shares authorized; 40,630,815 and 8,750,582 shares issued and outstanding as of December 31, 2025 and 2024, respectively 1,015,000 and 0 shares unvested as of December 31, 2025 and 2024, respectively | $406 | $87 | |
| Additional paid-in capital | $150.7M | $118.1M | |
| Accumulated deficit | -$80.6M | -$39.0M | |
| Total stockholders equity | $70.1M | $79.1M | $542.4K |
| Total liabilities and stockholders equity | $84.2M | $104.9M | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 100.0M shares | 100.0M shares | |
| Common stock, shares issued | 40.6M shares | 8.8M shares | |
| Common stock, shares outstanding | 40.6M shares | 8.8M shares | |
| Common stock, shares unvested | 1.0M shares | 0 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss from continuing operations | -$43.5M | -$18.8M |
| Depreciation expense | $2.0K | $2.0K |
| Amortization of intangible assets | $453.8K | |
| Change in fair value of warrant liability | -$909.0K | $183.0K |
| Change in fair value of derivative liability | -$2.3M | -$180.4K |
| Loss on conversion of note payable | $53.4K | |
| Loss on disposition of subsidiaries | $214.5K | |
| Stock-based compensation | $2.1M | $25.6K |
| Common stock issued for services | $4.3M | $4.6M |
| Goodwill impairment | $26.3M | |
| Impairment of investment | $2.5M | |
| Amortization of debt discount | $3.2M | $912.4K |
| Amortization of right-of-use assets | $35.9K | $51.4K |
| Interest income | -$250.0K | |
| Accounts receivable, net | -$720.2K | -$11.1K |
| Prepaid expenses and deposits | -$193.0K | $34.7K |
| Inventory | -$213.4K | $968 |
| Other receivables | -$80.5K | -$2.9M |
| Lease liability | -$37.0K | -$51.6K |
| Accounts payable | -$1.6M | $448.6K |
| Accrued liabilities | -$248.6K | -$44.6K |
| Current liabilities | -$5.4K | -$62.4K |
| Net cash used in operating activities from continuing operations | -$13.4M | -$13.3M |
| Net cash provided by (used in) operating activities from discontinued operations | $2.8K | -$979.1K |
| Net cash used in operating activities | -$13.4M | -$14.3M |
| Cash received in acquisition | $133.0K | |
| Acquisition of property and equipment | -$12.0K | |
| Investment in securities | -$2.5M | |
| Net cash used in investing activities from continuing operations | -$2.4M | |
| Net cash provided by investing activities from discontinued operations | $29.9M | |
| Net cash provided by investing activities | $27.6M | |
| Repayment of contingent liability | -$1.2M | |
| Proceeds from loan payable, related party | $116.0K | $150.0K |
| Repayment of loan payable, related party | -$531.0K | |
| Proceeds from issuance of convertible notes, net of issuance costs | $3.0M | |
| Proceeds from convertible notes | $3.5M | |
| Repayment of convertible notes | -$9.2M | |
| Gross proceeds from issuance of common stock | $26.3M | |
| Repayment of development liability | -$400.0K | |
| Cash dividends paid | -$14.9M | |
| Proceeds from exercise of warrants | $16.6K | |
| Proceeds from exercise of options | $9.8K | |
| Net cash provided by (used in) financing activities from continuing operations | $19.7M | -$13.0M |
| Net cash used in financing activities from discontinued operations | -$5.0K | |
| Net cash provided by (used in) financing activities | $19.7M | -$13.0M |
| Net change in cash | $6.4M | $307.8K |
| Conversion of note payable into common stock | $411.0K | |
| Equity line of commitment shares issued as offering costs | $1.5M | $534.8K |
| Issuance of note receivable in exchange for other receivables | $5.0M | |
| Issuance of shares pursuant to Merger | $78.6M | |
| Assets acquired in connection with Merger | $194.6K | |
| Liabilities assumed in connection with Merger | $5.8M | |
| Insurance premium financed | $198.2K | |
| Issuance of common shares in connection with converible debenture | $420.2K | |
| Deferred offering costs | $69.4K | |
| Derivative liability recognized in connection with issuance of convertible note | $2.5M | |
| Warrants issued with convertible note | $71.3K | |
| Common stock issued for convertible note settlement | $189.7K | |
| Common stock issued for convertible note extension | $175.2K | |
| Accretion of original issue discount on Treasury Bills | $20.6K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Scienture Holdings, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
201520202025
- Chief executive officerHariharan Shankar Mar 12, 2026 to now13
- Chief executive officerSurendra K. Ajjarapu Aug 14, 2014 to May 28, 202414
- ChairHariharan Shankar Mar 12, 2026 to now13
- ChairSurendra K. Ajjarapu Aug 14, 2014 to May 28, 202414
- Chief financial officerEric Michael Sherb Aug 31, 2026 to now15
- Chief financial officerJanet Huffman Apr 4, 2022 to Feb 24, 202316
- Chief financial officerHoward A. Doss Aug 14, 2014 to Apr 15, 202017
Board members and other officers (10)
- Board memberHariharan Shankar Aug 5, 2024 to Aug 5, 202418
- Board memberA. Jeffrey Newell Oct 14, 2022 to Dec 30, 202219
- Board memberChristine L. Jennings Jun 4, 2021 to Jun 4, 202120
- Board memberGary Augusta Oct 21, 2019 to Oct 21, 201921
- Board memberPamela Tenaerts Nov 22, 2019 to Apr 20, 202122
- Board memberMichael L. Peterson Feb 14, 2018 to Jan 20, 202323
- Board memberSurendra K. Ajjarapu Apr 24, 2017 to Sep 16, 202224
- Board memberDonald Almeida V. Jan 30, 2015 to Jan 30, 201525
- Board memberCharles L. Pope Aug 12, 2014 to Sep 16, 202226
- Board memberDonald G. Fell Aug 15, 2014 to Sep 16, 202227
Named in SEC Form D filings
People the company listed in its private-offering notices.
- Executive Officer, DirectorNarasimhan Mani named Dec 19, 2024 to Aug 7, 202528
- Executive Officer, DirectorShankar Hariharan named Dec 19, 2024 to Aug 7, 202528
- Executive Officer, DirectorPrashant Patel named Dec 19, 202429
- DirectorMayur G. Doshi named Dec 19, 2024 to Aug 7, 202528
- DirectorSubbarao G. Jayanthi named Dec 19, 2024 to Aug 7, 202528
Former names
Timeline
Filings
244 filings to the SEC since October 2021: 8 annual reports, 15 quarterly reports, 96 major events, 26 insider forms, 7 large holders, 3 private raises, 89 other. The latest 20:
- Oct 7, 20268-K EDGAR
- Sep 18, 2026DEF 14A EDGAR
- Sep 14, 20268-K EDGAR
- Sep 8, 2026PRE 14A EDGAR
- Aug 31, 20265 EDGAR
- Aug 31, 20263 EDGAR
- Aug 20, 20268-K EDGAR
- Aug 13, 202610-Q EDGAR
- May 29, 20268-K EDGAR
- May 22, 20268-K EDGAR
- May 15, 202610-Q EDGAR
- May 5, 20268-K EDGAR
- May 1, 20268-K EDGAR
- Apr 30, 202610-K/A EDGAR
- Mar 30, 202610-K EDGAR
- Mar 12, 20264 EDGAR
- Mar 12, 20264 EDGAR
- Nov 18, 20258-K EDGAR
- Nov 14, 20258-K EDGAR
- Nov 14, 2025SCHEDULE 13G/A EDGAR
The 244 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
4 open-market trades by officers, directors and large owners since October 2021: 4 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 25, 2022 | Fell Donald G.Director | Buy | 1,500 | $1.08 | $1.6K | Form 4 |
| May 20, 2022 | AJJARAPU SURENDRA KChairman and CEO | Buy | 10,000 | $1.30 | $13.0K | Form 4 |
| May 20, 2022 | AJJARAPU SURENDRA KChairman and CEO | Buy | 10,000 | $13,000.00 | $130.0M | Form 4 |
| May 12, 2022 | Fell Donald G.Director | Buy | 2,000 | $1.26 | $2.5K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- L1 Capital Global Opportunities Master Fund, Ltd.SCHEDULE 13G/A, 2 filings Aug 19, 2025 to Nov 14, 202530
- SCOGGIN MANAGEMENT LPSCHEDULE 13G, 1 filing Aug 20, 202531
- ARMISTICE CAPITAL, LLCSC 13G/A, 2 filings Feb 14, 2023 to Feb 14, 202432
- Prashant PatelSC 13D/A, 1 filing Oct 19, 202233
- Surendra K. AjjarapuSC 13D/A, 1 filing Oct 19, 202234
Money raised
Private offerings the company reported to the SEC on Form D.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18SEC EDGARHariharan Shankar, Board member
- 19SEC EDGARA. Jeffrey Newell, Board member
- 20SEC EDGARChristine L. Jennings, Board member
- 21SEC EDGARGary Augusta, Board member
- 22SEC EDGARPamela Tenaerts, Board member
- 23SEC EDGARMichael L. Peterson, Board member
- 24SEC EDGARSurendra K. Ajjarapu, Board member
- 25SEC EDGARDonald Almeida V., Board member
- 26SEC EDGARCharles L. Pope, Board member
- 27SEC EDGARDonald G. Fell, Board member
- 28
- 29
- 30
- 31
- 32
- 33
- 34